NeuroSense rises after Italy allows ALS study enrollment
16/11/2022 18:08
** Shares of Israel-based drug developer NeuroSense
Therapeutics Ltd NRSN.O rise 7.9% to $1.84, set for their
longest winning streak in 3 months
** Italian Medicines Agency approves patient enrollment for
a mid-stage study of NRSN's experimental drug to treat
amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's
disease
** NeuroSense's shares closed nearly 8% higher on Tuesday
after it received U.S. FDA approval to enroll patients in the
study
** Including session's gains, stock down ~27% YTD
(Reporting by Aditya Samal)
((Aditya.Samal@thomsonreuters.com;))